

About Wegovy™

(semaglutide) injection 2.4 mg

Wegovy™ for chronic weight management

Wegovy™ is indicated for use with a reduced calorie meal plan and increased physical activity for adults with:¹

- **Obesity**
- **or excess weight with weight related medical problems**

to help them lose weight and keep the weight off.

It is also the first-and-only prescription weight-loss medication with **once-weekly dosing**.¹




Obesity = BMI ≥ 30 kg/m²

Excess weight = BMI ≥ 27 kg/m²

$$\text{BMI} = \frac{\text{weight(kg)}}{\text{height}^2(\text{m}^2)}$$

A GLP-1 analogue

Wegovy™ is an analogue of the **human glucagon-like peptide-1 (GLP-1) hormone**. Patients taking Wegovy™ have a long-term weight management tool which may help them reduce their caloric intake. The effects are likely brought about by affecting appetite. **GLP-1 is a naturally-occurring hormone in the body.** Wegovy™ lowers body weight through decreased caloric intake.¹



What is Wegovy™?

What is the most important information you need to know about Wegovy™?

Please click [here](#) for Prescribing Information and Medication Guide

Please see additional Important Safety Information on the following page

The STEP clinical program

The safety and efficacy of Wegovy™ was evaluated in the **STEP (Semaglutide Treatment Effect in People with Obesity)** phase 3a clinical development program that consisted of:^{2,6}


4 Trials **~4,500** Adults **392** Centers **26** Countries



Trial design

The primary endpoint for all STEP trials is weight loss

Patients who participated in the STEP trials were randomized to receive either Wegovy™ (reduced calorie meal plan and increased physical activity) or placebo (reduced calorie meal plan and increased physical activity only), and evaluated over a 68-week period.²



In the STEP 1-4 trials, weight loss was measured by percent change in body weight as a primary endpoint. In the STEP 1-3 trials, the percent of patients who achieved ≥5% reduction in body weight was also a primary endpoint.²

STEP 1-3: Evaluating weight loss

STEP 1



The largest of the four trials; weight loss achieved in patients treated with Wegovy™ vs. placebo

1,961 adults

STEP 2



Weight loss achieved in patients with type 2 diabetes treated with Wegovy™ vs. placebo

1,210 adults

STEP 3



Weight loss achieved in patients treated with Wegovy™ in combination with intensive behavioral therapy vs. placebo

611 adults

STEP 4: Evaluating weight loss maintenance

STEP 4



Long-term weight loss and maintenance in patients treated with Wegovy™ vs. placebo

902 adults
Run-in period

803 adults
Randomized period

Results

In the STEP 1 trial, results showed that patients taking Wegovy™ achieved:

An average weight loss of **~15%** of body weight at **68-weeks** compared to 2.4% with placebo³



~85% of patients achieved 5% or more reduction in body weight in the Wegovy™ arm compared to 31.1% with placebo³

The most frequently reported adverse events among people treated with Wegovy™ in the STEP trials were nausea, diarrhea, vomiting, constipation, and abdominal pain.¹

Wegovy™ Indication and Important Safety Information

What is Wegovy™?

Wegovy™ (semaglutide) injection 2.4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep the weight off.

- Wegovy™ should be used with a reduced calorie meal plan and increased physical activity.
- Wegovy™ contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
- It is not known if Wegovy™ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
- It is not known if Wegovy™ can be used safely in people with a history of pancreatitis.
- It is not known if Wegovy™ is safe and effective for use in children under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy™? Wegovy™ may cause serious side effects, including:

- **Possible thyroid tumors, including cancer.** Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy™ and medicines that work like Wegovy™ caused thyroid tumors, including thyroid cancer. It is not known if Wegovy™ will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
- Do not use Wegovy™ if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use Wegovy™ if:

- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy™.

Before using Wegovy™, tell your healthcare provider if you have any other medical conditions, including if you:

- have or have had problems with your pancreas or kidneys.
- have type 2 diabetes and a history of diabetic retinopathy.
- have or have had depression, suicidal thoughts, or mental health issues.
- are pregnant or plan to become pregnant. Wegovy™ may harm your unborn baby. You should stop using Wegovy™ 2 months before you plan to become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if Wegovy™ passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy™ may affect the way some medicines work and some medicines may affect the way Wegovy™ works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy™ slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy™?

Wegovy™ may cause serious side effects, including:

- **inflammation of your pancreas (pancreatitis).** Stop using Wegovy™ and call your healthcare provider if you may feel severe pain in your stomach (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
- **gallbladder problems.** Wegovy™ may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Tell your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
- **increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, especially those who also take medicines for type 2 diabetes such as sulfonylureas or insulin.** This can be both a serious and common side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy™. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery.
- **kidney problems (kidney failure).** In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
- **serious allergic reactions.** Stop using Wegovy™ and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat.
- **change in vision in patients with type 2 diabetes.** Tell your healthcare provider if you have changes in vision during treatment with Wegovy™.
- **increased heart rate.** Wegovy™ can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes.
- **depression or thoughts of suicide.** You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse or worry you.
- **the most common side effects of Wegovy™ may include:** nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu and heartburn.

References

1. Wegovy™ (semaglutide) injection 2.4 mg Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc. 2021.
 2. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. *Obesity*. 2020; 28:1050-1061.
 3. Wilding JP, Batterham R, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. February 10, 2021.
 4. Davies M, Færch L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. *The Lancet*. March 2021.
 5. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *JAMA*. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
 6. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA*. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224